 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Characteristics and clinical prognosis of EGFR-mutant NSCLC with meningeal metastasis (LM)

Front Oncol: Characteristics and clinical prognosis of EGFR-mutant NSCLC with meningeal metastasis (LM)

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

rat lung

imaging pancreatic cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Meningeal metastasis (LM) is a common complication in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
.

Therefore, a team from Peking Union Medical College Hospital has carried out related research to study the gene mutation types, treatment strategies and clinical outcomes of patients with LM

Meningeal metastasis (LM) is a common complication in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)

We retrospectively analyzed the clinical characteristics and survival outcomes of 53 EGFR-mutant NSCLC patients with LM
.

Fifty patients were diagnosed with LM by CSF cytology, and 3 patients were diagnosed with LM by MRI

We retrospectively analyzed the clinical characteristics and survival outcomes of 53 EGFR-mutant NSCLC patients with LM

Median OS after LM diagnosis was 13 months (95% CI = 9.
067–16.
933)
.

Median OS after LM diagnosis was 13 months (95% CI = 9.

The median OS of patients with disease control (PR and SD) treated with LM after LM diagnosis was significantly longer than that of PD patients, 17.
0 months and 2.
5 months, respectively (HR=6.
800; 95% CI = 3.
365–13.
740; p < 0.
001) The median OS of patients with extracranial lesions obtained disease control (PR and SD) was also significantly longer than that of PD patients, 15.
0 months and 3.
5 months, respectively (HR=4.
286; 95% CI = 2.
089-8.
792; p = 0.
001 )
.

The median OS of patients with disease control (PR and SD) treated with LM after LM diagnosis was significantly longer than that of PD patients, 17.

The median OS of patients with no EGFR sensitive mutation detected in blood after LM diagnosis was significantly longer than that of patients with detected mutation, which were 17.
0 months and 7.
0 months, respectively ( HR=2.
000; 95% CI = 0.
965-4.
143; p = 0.
040); The median OS of patients treated with osimertinib after LM diagnosis was significantly longer than that of other treatment modalities, 15.
0 months and 6.
0 months, respectively (HR=2.
429; 95% CI = 1.
234-4.
779; p = 0.
045)
.

The median OS of patients with no EGFR sensitive mutation detected in blood after LM diagnosis was significantly longer than that of patients with detected mutation, 17.
0 months and 7.
0 months, respectively ( HR=2.
000; 95% CI = 0.
965-4.
143; p = 0.
040); The median OS of patients treated with osimertinib after LM diagnosis was significantly longer than that of other treatment modalities, 15.
0 months and 6.
0 months, respectively (HR=2.
429; 95% CI = 1.
234-4.
779; p = 0.
045)
.

The median OS of patients with no EGFR sensitive mutation detected in blood after LM diagnosis was significantly longer than that of patients with detected mutation, 17.

Logistic regression analysis showed that the control status of LM lesions was a positive predictor of OS after LM diagnosis (odds ratio: 10.
797; 95%CI = 4.
102 28.
419; p<0.
001)
.

Sex, age, ECOG PS, BM status, CSF EGFR mutation status, combined ITC, WBRT, and chemotherapy after LM diagnosis were not significantly associated with OS after LM diagnosis

Logistic regression analysis showed that the control status of LM lesions was a positive predictor of OS after LM diagnosis (odds ratio: 10.

Taken together, the study showed that osimertinib treatment had better clinical outcomes in patients with EGFR-mutant NSCLC after diagnosis of LM
.

Furthermore, LM lesion control is the most effective strategy for prolonging the overall survival outcome of these patients
.

Taken together, the study showed that osimertinib treatment had better clinical outcomes in patients with EGFR-mutant NSCLC after diagnosis of LM
.
Furthermore, LM lesion control is the most effective strategy for prolonging the overall survival outcome of these patients
.
Studies have shown that patients with EGFR-mutant NSCLC diagnosed with LM have better clinical outcomes with osimertinib treatment
.
Furthermore, LM lesion control is the most effective strategy for prolonging the overall survival outcome of these patients
.
Studies have shown that patients with EGFR-mutant NSCLC diagnosed with LM have better clinical outcomes with osimertinib treatment
.
Furthermore, LM lesion control is the most effective strategy for prolonging the overall survival outcome of these patients
.

Original source:

Li N, Bian Z, Cong M and Liu Y (2022) Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis.
Front.
Oncol.
11:723562.
doi: 10.
3389/fonc.
2021.
723562 .

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.